Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

Pfizer (PFE) to continue its BULL run in 2022!Fundamental Analysis Pfizer, Inc. has consistently been one of the largest pharmaceutical companies in the world for the better part of the last two decades. The company has a remarkable history going back all the way to the year 1849, when Pfizer was founded in Brooklyn, New York. The large cap pharma giant has developed a well-balanced and deep portfolio of products in key areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. However, it seems that as a result of the success of Pfizer's vaccine COVID-19 treatments, many investors have forgotten about the rest of Pfizer's business and how successful it continues to be. It is true that the sales of its COVID-19 vaccine ($36 billion in 2021 alone) have managed to nearly double Pfizer's annual revenue from $41.9 billion in 2020 to over $78 billion in 2021. What's even more important is that the strong sales growth has also translated into higher profits for the company as its profit margins before interest and taxes, referred to as EBIT margin, have risen over the past year. This shows that Pfizer has managed its R&D and all other fixed and operating costs associated with development, production and distribution efficiently, thus improving the profitability ratios of the company. The large cap pharma giant has also managed to almost triple the size of its free cash flow to more than $29 billion over the past twelve months compared to only $11.6 billion in 2020. More free cash flow makes a business more robust, giving Pfizer more money to invest in research and development of new products, pay more in dividends, or strengthen its balance sheet. The company currently has a total of 94 drugs in the pipeline spread across critical treatment areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. all waiting regulatory approval. - Phase 1(27); Phase 2 (29); Phase 3 (29); Registration (9) Looking at the outstanding track record of Pfizer's drug development capabilities, we can easily state that the company will continue to be a leader in the sector that it operates in. Macro view The equity markets in the US are currently undergoing a process of meaningful repricing and re-valuation of what companies are actually worth, as everyone is getting ready for the Federal Reserve to start raising interest rates in the US and tighten its monetary policy. In a rising interest rate environment, investors tend to move away from expensive high-growth stocks trading at unreasonably high P/E and P/S valuations as the tighter monetary policy environment makes it much more difficult and more expensive for such companies to borrow and invest capital and produce the high earnings growth that investors expect from them. Well-established large cap Healthcare and Biotech stocks are considered to be least correlated with the monetary policy situation in the country as they tend to trade more on FDA drug approvals and drug-related announcements rather than actual earnings per share. Most of the leaders in this space also have a substantial pricing power, as people using their medicines are doing so because they need them and because the drugs are helping them get better. Thus, owning Healthcare and Biotech stocks in a rising inflation and interest rate environment is a defensive play that could end up paying off big time, as stocks in these sectors are rather volatile. Technical Analysis The stock has experienced a volatile retracement from its $61 all-time highs and is currently in a corrective phase. However, the uptrend is still intact as the price is well above both the strong horizontal support at $51 and the upward sloping diagonal support (blue line) at $44. Furthermore, the stock is trading above its 5, 20, 50, 200 EMAs, which is also a bullish continuation signal. We expect buyers to start coming in around the $52-53 level, thus establishing the next higher high. Once that is done, the stock will re-test its ATH at around $61 in Q1 of this year. The broad market framework, together with the many positive company related developments in the coming months are expected to bring enough momentum to the stock in order for it to break its previous ATH and set a new one sometime in Q2. Our target for the stock in H1 of 2022 is around the $68 level, which is roughly 30% higher from the current levels. Follow and Copy us on eToro for more detailed market analyses, profitable trading ideas and a consistent portfolio performance. [ b] Sincerely, @DowExperts
NYSE:PFELong
by DowExperts
$PFEBreakout zones: $55.7 $55.34 Bull PT: $56. 05 $56.84 $57.58 Bear PT: $54.87 $54.27 $53.5 $52.73 $PFE, as of right now is fairly flat. However, taking note of the 1HR, this is a previous chop zone before the run on 12/15. $PFE chopped here for two days before the consolidation drove the price higher. If we take a closer look at the 1HD something seems off, im noticing a top and if we take the 12/13-12/14 chop its a formed a shoulder in this area. Now, to confirm that bias we take it to the D. This would prove the hypothesis correct. $PFE is too top heavy and now in its correction. The daily shows an ugly H/S, dangle how is that a H/S. Not everything is symmetrical. lets take a look at our indicators. AO, double top or "twin peak" working its way down now. RSI , showing us divergence to the downside. very healthy. there is a little "curl/tail" however we are fairly neutral but still leaning to complete this pullback.
NYSE:PFE
by thelowestdange
PFE retested breakout. Whats? nextIf you look at my previous idea on PFE you'll see that I said pre would hit 60$ if it broke out and we did visit 60$ before pulling back to retest the breakout. We close on 2 strong supports.. yellow lines ( channel) purpleline (Support). Now tomorrow we have 2 paths, if we bounce our next leg up would be to 67$ or channel top. If we break support that would be bad, and I think we'd immediately close the gap left behind at 52.85 MACD- bearish RSI - Bearish ALSO worth noting is our 21ema aligns with our purple support which adds more strength. Let's see what happens
NYSE:PFE
by ContraryTrader
6
Pfizer | Fundamental Analysis | LONG SETUP ⚡️Pharmaceutical giant Pfizer has been at the forefront of the industry, developing drugs to treat COVID since the pandemic began. Unfortunately, the world continues to struggle with different strains of the virus, most recently with the Omicron variant, but Pfizer's products are still in high demand, which will likely boost its results in 2022. It's been about a year since the first COVID vaccine became available in the U.S., and a race has begun to ramp up production and dose distribution. Several companies have been working on vaccines, but the market has become a two-company market. The vast majority of the doses administered in the U.S. came from Pfizer and Moderna, two companies that developed vaccines using mRNA technology. Pfizer and Moderna have developed mRNA vaccines that use the genetic code of the virus to trigger an antibody response in the human body. Traditional vaccines use an attenuated form of the whole virus, which teaches the body to defend itself against it. This is essentially similar to how the body develops immunity after a person gets chickenpox, but the weakened virus does not make the person sick. Both types of vaccines achieve similar results, but pharmaceutical companies can reproduce the genetic code for production faster and easier than the virus itself. Demand for the vaccine has increased primarily because of the ability of the virus to mutate into new variants. Initially, Pfizer's vaccine was supposed to treat with two doses, but as new variants emerged, many began to give a third shot (called a booster). Pfizer's original 2021 forecast called for 1.3 billion doses, but it ended up producing about 3 billion doses in 2021. Now, the company's management predicts that Pfizer will produce about 4 billion doses in 2022. This is a tragic and challenging time for society as the pandemic continues, but Pfizer's leadership position has created tremendous benefits for the company. First, the actual sales of its vaccine have been enormous: The company's expected revenue in 2021 was $36 billion. By comparison, Pfizer's 2020 revenue was $41.9 billion; this means that the COVID vaccine nearly doubled Pfizer's business! What's more, it was profitable for Pfizer. The company's earnings before interest and taxes, called EBIT margin, increased over the past year as the vaccine business grew. The company has also significantly increased free cash flow, which was more than $29 billion in the past twelve months, up from $11.6 billion in 2020. Increased free cash flow makes the business more sustainable, which gives Pfizer more money to invest in research and new product development, pay dividends, or strengthen its balance sheet. As the Omicron option spreads, it is becoming more likely that COVID will not disappear entirely shortly. Pfizer recently developed an oral antiviral pill to treat early-stage COVID symptoms, and company executives estimate that 80 million courses of treatment could be produced in 2022. Although our focus today is on the next twelve months, Pfizer could potentially profit from the COVID treatment for several years. Investors have reacted to Pfizer's COVID success; the company's stock is up 56% in the last year, a big gain for a company with a market value of $329 billion. Still, the market may not be valuing Pfizer highly enough. If we want to value a stock by the amount of free cash flow that investors receive per share, we can look at the free cash flow yield; this percentage reflects how much of the stock price investors receive in free cash flow. We want to get as much free cash flow for our money as we can because it pays dividends, funds new products, and generally creates value for shareholders - it's like the "lifeblood" of a company. Accounting or non-cash items can affect earnings, so free cash flow can provide a fresh perspective on stock valuation. Pfizer's increase in free cash flow this year resulted in higher returns because free cash flow grew faster than the stock price. Now that the stock has started to rise, yields are down, but we are still near multi-year highs, which means that the stock offers you more "value for your money" than it has for most of the last ten years. In other words, they are still cheap. With COVID firmly entrenched in our world, Pfizer retains its chances of success in 2022.
NYSE:PFELong
by FOREXN1
4
$PFE READY FOR A BIG MOVE!!$PFE is currently trading in a descending triangle and looking to make a big move in either direction. The flow is mixed, though there has been a lot of unusual call flow coming in for $PFE in the last few days, so do keep that in mind. Let me know your thoughts down below, but I personally believe that we can see another leg up before finally topping out. It is making the same pattern that it did back in early December, which led to a 16%+ move in the stock price.
NYSE:PFELong
by krislee007jb
PFIZER SANTA RALLY?Pfizer Pfizer Pfizer where do i start? over the past month Pfizer has been on an uptrend. good news bad news omicron covid etc. this thing just keeps going and i do not think it’s done. i have been scalping this over the past two weeks and on Friday we closed on an inside bar on the 30-minute window which we can see is a period of consolidation. i think Pfizer break outs from here. i am typing my ideas after a long 10-hour shift so I will try to just list out my indicators and why i say it will break out from here. also, i am a beginner so bear with me. - I use Wyse trade fib retracement between .618 and .50 for confirmation on entries. using this fib from that gap down on the 21st shows us that we have a solid entry for calls here. that paired up with the 9ema touching the inside bar that we closed with on the last trading day gives me more conviction to go long on this trade. - also, Pfizer pill is now a thing so that’s even more bullish if that works. - to get more technical price bounced back to the 58.70 level which is a newly formed level of support over the past week coming off all-time highs. - using the tradingwarz fib retracement after the price came back to support the apparent uptrend that was coming, shorts tried to short this down again to break support but that didn’t happen. the fib shows us that we fell a little under the .78 on the 30 min chart. - considering that we are on this same type of scenario now I think that a price target following the fib we could see mid 62 or even 63s this week on Pfizer let’s see how this plays out.
NYSE:PFELong
by kimololaurian
Possible Pfizer Play AlertPfizer has had exponential growth over the past few months with delta variant and most recent omicron variant. Through these ideas we have seen billions of vaccines purchased by other countries and the United States. U.S just administered 500 million doses along with that the FDA just gave the green light to oral antiviral pill. We see a double touch and fall leading to a big jump after a consolidation period in the end of November to early December and right now we are sitting in that exact same bout again and all these purchases of vaccines and antiviral pills being released. Its prominent that Pfizer is bound to reach new highs especially within the early months of 2022. First few calls initiated at 60.3 and a load in the 61.55 zone as we break resistance lines. Stikes: January 28 2022-63 dollar calls- 20% chance of profit- Greeks showing decline of .03 a day with a delta of roughly .3 off the dollar jump
NYSE:PFELong
by haydencrann